Skip to main content
ALMS
NASDAQ Life Sciences

Foresite Capital and Director Tananbaum Invest $10.6M in Alumis Stock

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$21.08
Mkt Cap
$2.574B
52W Low
$2.76
52W High
$22.3
Market data snapshot near publication time

summarizeSummary

This Schedule 13D/A filing reveals that Foresite Capital, a major institutional shareholder, and James B. Tananbaum, a director of Alumis Inc. and managing member of Foresite entities, have significantly increased their beneficial ownership. The group acquired approximately $3.6 million in open market purchases in November 2025 and an additional $7.0 million in the company's follow-on offering on January 8, 2026. These substantial investments, totaling around $10.6 million, demonstrate strong conviction from a key investor and insider, particularly following a period of dilution. The participation in the follow-on offering at $17.00 per share, compared to the current stock price of $21.08, suggests confidence in the company's valuation and future prospects.


check_boxKey Events

  • Significant Insider/Institutional Purchases

    Foresite Capital and director James B. Tananbaum acquired approximately $10.6 million worth of Alumis Inc. common stock.

  • Follow-on Offering Participation

    The group purchased $7.0 million in shares at $17.00 per share as part of the company's January 8, 2026 follow-on offering.

  • Open Market Acquisitions

    An additional $3.6 million in shares were acquired through open market purchases in November 2025.

  • Increased Beneficial Ownership

    The reporting persons collectively hold 14.1% of Alumis Inc.'s common stock.


auto_awesomeAnalysis

This Schedule 13D/A filing reveals that Foresite Capital, a major institutional shareholder, and James B. Tananbaum, a director of Alumis Inc. and managing member of Foresite entities, have significantly increased their beneficial ownership. The group acquired approximately $3.6 million in open market purchases in November 2025 and an additional $7.0 million in the company's follow-on offering on January 8, 2026. These substantial investments, totaling around $10.6 million, demonstrate strong conviction from a key investor and insider, particularly following a period of dilution. The participation in the follow-on offering at $17.00 per share, compared to the current stock price of $21.08, suggests confidence in the company's valuation and future prospects.

في وقت هذا الإيداع، كان ALMS يتداول عند ‏٢١٫٠٨ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٢٫٦ مليار US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ‏٢٫٧٦ US$ و‏٢٢٫٣٠ US$. تم تقييم هذا الإيداع على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٨ من 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ALMS - Latest Insights

ALMS
Mar 30, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
9
ALMS
Mar 19, 2026, 5:02 PM EDT
Filing Type: S-3ASR
Importance Score:
7
ALMS
Mar 19, 2026, 4:23 PM EDT
Filing Type: 10-K
Importance Score:
8
ALMS
Mar 19, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
9
ALMS
Mar 19, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
ALMS
Jan 13, 2026, 6:20 PM EST
Filing Type: 4
Importance Score:
7
ALMS
Jan 13, 2026, 6:18 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
ALMS
Jan 12, 2026, 9:59 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
ALMS
Jan 09, 2026, 6:02 AM EST
Filing Type: 8-K
Importance Score:
8
ALMS
Jan 08, 2026, 5:29 PM EST
Filing Type: 424B5
Importance Score:
8